Nasdaq GlobeNewswire

B-Temia and Wistron Join Forces to Launch Keeogo(TM) in Asia

Del

B-Temia and Wistron form B-Temia Asia to bring Keeogo(TM) to the Asian Market

QUEBEC CITY, June  07, 2018  (GLOBE NEWSWIRE) -- B-Temia Inc., a Canadian biorobotics technology company and market leader in human mobility, entered into a joint venture agreement with Wistron Corporation to launch its Keeogo(TM) Dermoskeleton(TM) technology in Asia. Wistron is one of the world's largest Original Design Manufacturer (ODM), with more than $34 billion CAD sales, and now a major shareholder of B-Temia since June 2017. Wistron and B-Temia form B-Temia Asia for the marketing of Keeogo(TM) in several Asian countries such as China, Japan and Hong Kong. Headquartered in Singapore, B-Temia Asia will benefit from a significant investment from Wistron in exchange for marketing rights for Keeogo(TM) products in Asia.

"B-Temia Asia represents the realization of our business plan and our mission to help people regain their independence through mobility. B-Temia is now expanding around the world, which is another demonstration of the real value of our technology and the need to bring modern and revolutionary solutions to the many people living with mobility limitations. In addition, we are excited to expand and strengthen our partnership with Wistron. Over the last year, both organizations have effectively proven their ability to work together for manufacturing transfer to Asia. This joint venture is the next logical step for Wistron, which became a major shareholder of our company in 2017", said Stéphane Bédard, CEO of B-Temia. "This international expansion is a very exciting time for our shareholders said Mr. Bédard.

"Wistron is advancing the development and application of medical technologies to help people with mobility challenges and we are very excited to increase our partnership with B-Temia and to work closely together to develop the human mobility market in Asia. This partnership directly supports our goal of improving people's lives through technology", said Donald Hwang, Chief Technology Officer (CTO) of Wistron Corporation.

About Keeogo(TM) Dermoskeleton(TM)

Keeogo(TM) is a motorized walking assistive device developed by B-Temia. Keeogo(TM), short for "Keep on Going", has been used by people suffering from degenerative diseases such as osteoarthritis of the knee or hip, multiple sclerosis, Parkinson's disease, stroke, incomplete spinal cord injury and other mobility-limiting diseases. Used as a rehabilitation equipment or as a home assistive device to help with daily activities, Keeogo(TM) is approved by Health Canada and is commercially available in Canada for purchase or rental. For more information, please visit: www.keeogo.com.

About B-Temia

Founded in 2010, B-Temia Inc. is an innovative Canadian medical device manufacturer that develops and markets leading edge products for the growing market of human augmentation systems. B-Temia operates through two wholly owned subsidiaries, B-Temia Inc. and B-Temia USA Inc., in the medical, industrial and military fields. B-Temia has a patented technology called Dermoskeleton(TM) that restores, maintains or enhances user mobility. For more information, please visit: www.b-temia.com.

About Wistron

Wistron Corporation is one of the world's largest companies to produce servers and storage devices for cloud computing and data centers, desktop and laptop computers, smart phones, industrial devices and control units, medical devices, Artificial Intelligence and Big Data Analysis. Wistron's full line of engineering teams enables Wistron's customers to outsource all or part of their product development and manufacturing tasks to focus on their core competencies and further develop their intellectual properties. Wistron manufactures medical products for customers in the medical industry at two ISO 13485-certified factories in Taiwan's Hsinchu Science Park and in Chongqing, China. For more information, please visit: www.wistron.com.

Information

Source:
B-Temia Inc.
4780, St-Félix Street, Suite 105
St-Augustin (Québec) G3A 2J9
www.b-temia.com | www.keeogo.com
Phone: (418) 653-1010
E-mail: info@b-temia.com

 
Media:
Pamela Borges
VP Market Access & External Affairs
Phone: (418) 653-1010, ext. 223
E-mail: pamela.borges@b-temia.com





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: B-Temia Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Platinum Equity to Sell Worldwide Flight Services for €1.2 Billion19.6.2018 15:00Pressemelding

Successful investment adds to Platinum Equity's continued momentum in Europe LOS ANGELES, June 19, 2018 (GLOBE NEWSWIRE) -- Platinum Equity today announced it has signed a definitive agreement to sell Worldwide Flight Services (WFS) to affiliates of Cerberus Capital Management, L.P. in a transaction valued at approximately €1.2 billion. The sale is expected to close during Q4 2018, subject to regulatory approval and certain closing conditions. Since Platinum Equity acquired the company in 2015, WFS has grown significantly, both organically and through a transformative add-on acquisition, and is now the world's largest air cargo handler and one of the world's leading providers of ground handling and technical services, with annual revenues of more than €1.2 billion. "Through a combination of growth and operational initiatives, WFS has evolved and expanded significantly over the past three years and today enjoys record top-line and earnings performance," said Platinum Equity Partner Loui

Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00Pressemelding

SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00Pressemelding

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P

Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44Pressemelding

YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon

Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00Pressemelding

AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by

PubMatic Launches PubMatic Cloud to Evolve the SSP Business Model19.6.2018 09:00Pressemelding

New offering provides publishers and tech companies with a transparent alternative to revenue shares REDWOOD CITY, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced the launch of PubMatic Cloud for publishers and tech companies looking to implement and control their own programmatic technology. By accessing PubMatic's technology, global infrastructure and demand connections on a platform-as-a-service (PaaS) basis, clients are able to achieve full transparency and achieve greater control over their programmatic monetization. As programmatic trading becomes mainstream, innovations such as header bidding and fraud controls have resulted in gains for publishers. However, it has also contributed to the ballooning of infrastructure costs and overhead to manage integrations with the buy-side and third-party technology vendors as well as continuously evolving technology. The ability to keep pace

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom